-
1دورية أكاديمية
المؤلفون: Mirza, Mansoor R., Monk, Bradley J., Herrstedt, Jørn, Oza, Amit M., Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Ledermann, Jonathan A., Lorusso, Domenica, Vergote, Ignace, Ben-Baruch, Noa E., Marth, Christian, Mądry, Radosław, Christensen, René D., Berek, Jonathan S., Dørum, Anne, Tinker, Anna V., du Bois, Andreas, González-Martín, Antonio, Follana, Philippe, Benigno, Benedict, Rosenberg, Per, Gilbert, Lucy, Rimel, Bobbie J., Buscema, Joseph, Balser, John P., Agarwal, Shefali, Matulonis, Ursula A.
مرشدي الرسالة: Univ Arizona
الوصف: BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer. METHODS In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2: 1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. RESULTS Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P < 0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. CONCLUSIONS Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274.)
الإتاحة: http://hdl.handle.net/10150/622478Test
http://arizona.openrepository.com/arizona/handle/10150/622478Test -
2دورية أكاديمية
المؤلفون: Mirza, Mansoor R, González-Martín, Antonio, Graybill, Whitney S, O'Malley, David M, Gaba, Lydia, Stephanie Yap, Oi Wah, Guerra, Eva M, Rose, Peter G, Baurain, Jean-François, Ghamande, Sharad A, Denys, Hannelore, Prendergast, Emily, Pisano, Carmela, Follana, Philippe, Baumann, Klaus, Calvert, Paula M, Korach, Jacob, Li, Yong, Malinowska, Izabela A, Gupta, Divya, Monk, Bradley J
المصدر: FUTURE ONCOLOGY ; ISSN: 1479-6694 ; ISSN: 1744-8301
مصطلحات موضوعية: Medicine and Health Sciences, Cancer Research, Oncology, General Medicine
الوصف: What is this summary about? This document provides a summary of results from the article that evaluated the safety and efficacy of the fixed and individualized starting doses of niraparib in the PRIMA study. The original article was published in the journal Cancer in March 2023. The PRIMA study included adult patients with newly diagnosed advanced ovarian cancer who had finished treatment with chemotherapy and surgery. Once patients entered the study, they were treated with an oral (by mouth) medication called niraparib or placebo (substance with no effects that a doctor gives to a patient instead of a drug). The amount of drug (dose) prescribed for patients to take at the start of treatment was determined by the study plan (a document that describes in detail how the study will be performed). Some patients were treated with a fixed starting dose (300 milligrams [mg] once daily), while others were treated with an individualized dose (200 or 300 mg once daily) based on how much they weighed and the results of their blood test. The individualized dose was tested to see if it improved patient safety without changing its efficacy (how well the drug worked). What were the results? The individualized starting dose of niraparib improved patient safety, with a lower proportion of patients experiencing side effects than the fixed starting dose. The individualized starting dose of niraparib also delayed the cancer from coming back (recurring) or getting worse (progressing) compared with placebo. The delay in the cancer coming back or getting worse with niraparib treatment was generally similar in patients who received the individualized starting dose and those who received the fixed starting dose of niraparib. What do the results mean? The results support the use of the individualized starting dose of niraparib, which uses a patient's body weight and blood test results to determine how much drug they should receive at the start of treatment. The study found that the individualized starting dose improved safety compared ...
وصف الملف: application/pdf
العلاقة: https://biblio.ugent.be/publication/01HSJTGYDDG6S7N03M9VR2R97ZTest; http://hdl.handle.net/1854/LU-01HSJTGYDDG6S7N03M9VR2R97ZTest; http://doi.org/10.2217/fon-2023-0755Test; https://biblio.ugent.be/publication/01HSJTGYDDG6S7N03M9VR2R97Z/file/01HSJTPC3XA40XM34FKDGZK48ATest
الإتاحة: https://doi.org/10.2217/fon-2023-0755Test
https://biblio.ugent.be/publication/01HSJTGYDDG6S7N03M9VR2R97ZTest
http://hdl.handle.net/1854/LU-01HSJTGYDDG6S7N03M9VR2R97ZTest
https://biblio.ugent.be/publication/01HSJTGYDDG6S7N03M9VR2R97Z/file/01HSJTPC3XA40XM34FKDGZK48ATest -
3دورية أكاديمية
المؤلفون: Gonzalez-Martin, Antonio, Pothuri, Bhavana, Vergote, Ignace, Graybill, Whitney, Lorusso, Domenica, McCormick, Colleen C., Freyer, Gilles, Backes, Floor, Heitz, Florian, Redondo, Andres, Moore, Richard G., Vulsteke, Christof, O'Cearbhaill, Roisin E., Malinowska, Izabela A., Shtessel, Luda, Compton, Natalie, Mirza, Mansoor R., Monk, Bradley J.
المصدر: 1479-6694 ; Future oncology
مصطلحات موضوعية: Human medicine
الوصف: What is this summary about? This PLSP provides a short summary of an original scientific article that presented results from the PRIMA study after 3.5 years of follow-up time. The original article was published in the European Journal of Cancer in 2023. The PRIMA study included adult patients with newly diagnosed advanced high-risk ovarian cancer whose tumors shrunk or became undetectable after treatment with chemotherapy with or without surgery. The PRIMA study evaluated how well the drug niraparib, also known as Zejula, worked at delaying or preventing ovarian cancer from coming back (recurring) or getting worse (progressing) compared with placebo (a substance with no effects that a doctor gives to a patient instead of a drug). The first results from the PRIMA study were published in 2019, when patients had participated in the PRIMA study for about 1.2 years. The article this PLSP is based on reports longer-term data from the PRIMA study, when patients had participated in the PRIMA study for about 3.5 years. Patients were monitored (or followed) for a longer time to understand how well niraparib continued to work and to evaluate whether the safety of niraparib changed with additional time being monitored.
العلاقة: info:eu-repo/semantics/altIdentifier/isi/001187364100001
-
4دورية أكاديمية
المؤلفون: Mirza, Mansoor R, Chase, Dana M, Slomovitz, Brian M, dePont Christensen, René, Novák, Zoltán, Black, Destin, Gilbert, Lucy, Sharma, Sudarshan, Valabrega, Giorgio, Landrum, Lisa M, Hanker, Lars C, Stuckey, Ashley, Boere, Ingrid, Gold, Michael A, Auranen, Annika, Pothuri, Bhavana, Cibula, David, McCourt, Carolyn, Raspagliesi, Francesco, Shahin, Mark S, Gill, Sarah E, Monk, Bradley J, Buscema, Joseph, Herzog, Thomas J, Copeland, Larry J, Tian, Min, He, Zangdong, Stevens, Shadi, Zografos, Eleftherios, Coleman, Robert L, Powell, Matthew A
المساهمون: Mirza, Mansoor R, Chase, Dana M, Slomovitz, Brian M, dePont Christensen, René, Novák, Zoltán, Black, Destin, Gilbert, Lucy, Sharma, Sudarshan, Valabrega, Giorgio, Landrum, Lisa M, Hanker, Lars C, Stuckey, Ashley, Boere, Ingrid, Gold, Michael A, Auranen, Annika, Pothuri, Bhavana, Cibula, David, McCourt, Carolyn, Raspagliesi, Francesco, Shahin, Mark S, Gill, Sarah E, Monk, Bradley J, Buscema, Joseph, Herzog, Thomas J, Copeland, Larry J, Tian, Min, He, Zangdong, Stevens, Shadi, Zografos, Eleftherio, Coleman, Robert L, Powell, Matthew A
مصطلحات موضوعية: Dostarlimab, Primary Advanced, Endometrial Cancer
الوصف: Background: Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer. Methods: We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial. Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus carboplatin (area under the concentration-time curve, 5 mg per milliliter per minute) and paclitaxel (175 mg per square meter of body-surface area), every 3 weeks (six cycles), followed by dostarlimab (1000 mg) or placebo every 6 weeks for up to 3 years. The primary end points were progression-free survival as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, and overall survival. Safety was also assessed. Results: Of the 494 patients who underwent randomization, 118 (23.9%) had mismatch repair-deficient (dMMR), microsatellite instability-high (MSI-H) tumors. In the dMMR-MSI-H population, estimated progression-free survival at 24 months was 61.4% (95% confidence interval [CI], 46.3 to 73.4) in the dostarlimab group and 15.7% (95% CI, 7.2 to 27.0) in the placebo group (hazard ratio for progression or death, 0.28; 95% CI, 0.16 to 0.50; P<0.001). In the overall population, progression-free survival at 24 months was 36.1% (95% CI, 29.3 to 42.9) in the dostarlimab group and 18.1% (95% CI, 13.0 to 23.9) in the placebo group (hazard ratio, 0.64; 95% CI, 0.51 to 0.80; P<0.001). Overall survival at 24 months was 71.3% (95% CI, 64.5 to 77.1) with dostarlimab and 56.0% (95% CI, 48.9 to 62.5) with placebo (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.87). The most common adverse events that occurred or worsened during treatment were nausea (53.9% of the patients in the dostarlimab group and 45.9% of those in the placebo group), alopecia (53.5% and 50.0%), ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36972026; volume:Mar 27; firstpage:1; lastpage:14; numberofpages:14; journal:THE NEW ENGLAND JOURNAL OF MEDICINE; https://hdl.handle.net/2318/1898296Test
-
5دورية أكاديمية
المؤلفون: Mirza, Mansoor R, González-MartÃn, Antonio, Graybill, Whitney S, O'Malley, David M, Gaba, Lydia, Stephanie Yap, Oi Wah, Guerra, Eva M, Rose, Peter G, Baurain, Jean-François, Ghamande, Sharad A, Denys, Hannelore, Prendergast, Emily, Pisano, Carmela, Follana, Philippe, Baumann, Klaus, Calvert, Paula M, Korach, Jacob, Li, Yong, Malinowska, Izabela A, Gupta, Divya, Monk, Bradley J
المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'oncologie médicale, UCL - (SLuc) Centre du cancer
المصدر: Cancer, Vol. 129, no.12, p. 1846-1855 (2023)
مصطلحات موضوعية: Female, Humans, Body Weight, Carcinoma, Ovarian Epithelial, Indazoles, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Prospective Studies, individualized starting dose, niraparib, ovarian cancer, poly(ADP-ribose) polymerase inhibitors/adverse effects, poly(ADP-ribose) polymerase inhibitors/therapeutic use
الوصف: BACKGROUND: The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) trial was amended to prospectively evaluate the safety and efficacy of an individualized starting dose (ISD) regimen of niraparib for first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. METHODS: In the phase 3 PRIMA trial, patients with newly diagnosed advanced ovarian cancer with a complete/partial response to first-line platinum-based chemotherapy (N = 733) were initially treated with a fixed starting dose (FSD) regimen of 300 mg once daily. Subsequently, the protocol was amended so newly enrolled patients received an ISD: 200 mg once daily in patients with baseline body weight < 77 kg or baseline platelet count < 150,000/µL, and 300 mg once daily in all other patients. Efficacy and safety outcomes were assessed by starting dose. RESULTS: Overall, 475 (64.8%) patients were assigned to an FSD (niraparib, n = 317; placebo, n = 158) and 258 (35.2%) were assigned to an ISD (niraparib, n = 170; placebo, n = 88). Efficacy in patients who received FSD or ISD was similar for the overall (FSD hazard ratio [HR], 0.59 [95% CI, 0.46-0.76] vs. ISD HR, 0.69 [95% CI, 0.48-0.98]) and the homologous recombination-deficient (FSD HR, 0.44 [95% CI, 0.30-0.64] vs. ISD HR, 0.39 [95% CI, 0.22-0.72]) populations. In patients with low body weight/platelet count, rates of grades ≥3 and 4 hematologic treatment-emergent adverse events, dose interruptions, and dose reductions were lower for those who received ISD than for those who received FSD. CONCLUSIONS: In PRIMA, similar dose intensity, similar efficacy, and improved safety were observed with the ISD compared with the FSD regimen.
العلاقة: boreal:288952; http://hdl.handle.net/2078.1/288952Test; info:pmid/37060236; urn:ISSN:0008-543X; urn:EISSN:1097-0142
-
6دورية أكاديمية
المؤلفون: Gonzalez-Martin, Antonio, Pothuri, Bhavana, Vergote, Ignace, Graybill, Whitney, Lorusso, Domenica, McCormick, Colleen C., Freyer, Gilles, Backes, Floor, Heitz, Florian, Redondo, Andres, Moore, Richard G., Vulsteke, Christof, O'Cearbhaill, Roisin E., Malinowska, Izabela A., Shtessel, Luda, Compton, Natalie, Mirza, Mansoor R., Monk, Bradley J.
المصدر: 0959-8049 ; European journal of cancer
مصطلحات موضوعية: Human medicine
الوصف: Purpose: To report updated long-term efficacy and safety from the double-blind, placebo-controlled, phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016).Methods: Patients with newly diagnosed advanced ovarian cancer with complete or partial response (CR or PR) to first-line platinum-based chemotherapy received niraparib or placebo once daily (2:1 ratio). Stratification factors were best response to first-line chemotherapy re-gimen (CR/PR), receipt of neoadjuvant chemotherapy (yes/no), and homologous re-combination deficiency (HRD) status (deficient [HRd]/proficient [HRp] or not determined). Updated (ad hoc) progression-free survival (PFS) data (as of November 17, 2021) by in-vestigator assessment (INV) are reported. Results: In 733 randomised patients (niraparib, 487; placebo, 246), median PFS follow-up was 3.5 years. Median INV-PFS was 24.5 versus 11.2 months (hazard ratio, 0.52; 95% confidence interval [CI], 0.40-0.68) in the HRd population and 13.8 versus 8.2 months (ha-zard ratio, 0.66; 95% CI, 0.56-0.79) in the overall population for niraparib and placebo, respectively. In the HRp population, median INV-PFS was 8.4 versus 5.4 months (hazard ratio, 0.65; 95% CI, 0.49-0.87), respectively.Results were concordant with the primary analysis. Niraparib-treated patients were more likely to be free of progression or death at 4 years than placebo-treated patients (HRd, 38% versus 17%; overall, 24% versus 14%). The most common grade & GE; 3 treatment-emergent adverse events in niraparib patients were thrombocytopenia (39.7%), anaemia (31.6%), and neutropenia (21.3%). Myelodysplastic syndromes/acute myeloid leukaemia incidence rate (1.2%) was the same for niraparib-and placebo-treated patients. Overall survival remained immature.Conclusions: Niraparib maintained clinically significant improvements in PFS with 3.5 years of follow-up in patients with newly diagnosed advanced ovarian cancer at high risk of pro-gression irrespective of HRD status. No new safety signals were identified.& COPY; 2023 ...
العلاقة: info:eu-repo/semantics/altIdentifier/isi/001045038900001
-
7دورية أكاديمية
المؤلفون: Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle L., Mirza, Mansoor R., Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, McNeish, Iain, Kelly, Caroline, Kagimura, Tatsuo, Welch, Stephen, Lewsley, Liz-Anne, Paoletti, Xavier, Cook, Adrian
الوصف: Background In patients with advanced ovarian cancer, the modelled CA-125 ELIMination rate constant K (KELIM) is an early indicator of the tumour intrinsic chemosensitivity. We assessed the prognostic and surrogate values of KELIM with respect to those of surgery outcome (based on post-operative residual lesions) in the Gynaecologic Cancer Intergroup (GCIG) individual patient data meta-analysis MAOV (Meta-Analysis in OVarian cancer) built before the emergence of poly(ADP-ribose) polymerase (PARP) inhibitors. Methods: The dataset was split into learning and validation cohorts (ratio 1:2). The individual modelled KELIM values were estimated, standardised by the median value, then scored as unfavourable (<1.0) or favourable (≥1.0). Overall survival (OS) and progression-free survival (PFS) analyses were performed with a two-step meta-analytic approach and surrogacy through a two-level meta-analytic model. Results: KELIM was assessed in 5884 patients from eight first-line trials (learning, 1962; validation, 3922). A favourable KELIM score was significantly associated with longer OS (validation set, median, 78.8 versus 28.4 months, hazard-ratios [HR] 0.46, 95% confidence interval [CI], 0.41–0.50, C-index 0.68), and longer PFS (validation set, median 30.5 versus 9.8 months, HR 0.49, 95% CI, 0.45–0.54, C-index 0.68), as were International Federation of Gynaecology and Obstetrics (FIGO) stage and debulking surgery outcome. Three prognostic groups were identified based on the surgery outcome and KELIM score, with large differences in OS (105.1, ∼45.0, and 22.1 months) and PFS (58.1, ∼15.0, and 8.0 months). Surrogacy for OS and for PFS was not established. Conclusion: KELIM is an independent prognostic biomarker for survival, complementary to surgery outcome, representing a new determinant of first-line treatment success.
وصف الملف: text
العلاقة: https://eprints.gla.ac.uk/306786/1/306786.pdfTest; Corbaux, P. et al. (2023) Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis. European Journal of Cancer , 191, 112966. (doi:10.1016/j.ejca.2023.112966 ) (PMID:37542936)
-
8دورية أكاديمية
المؤلفون: Monk, Bradley J, González-Martin, Antonio, Buckley, Lynn, Matulonis, Ursula A., Rimel, B J, Wu, Xiaohua, Moore, Kathleen N, Mirza, Mansoor R
المساهمون: GSK
المصدر: International Journal of Gynecologic Cancer ; volume 33, issue 6, page 971-981 ; ISSN 1048-891X 1525-1438
الوصف: Niraparib is a poly (ADP-ribose) polymerase inhibitor that has shown a significant improvement in progression-free survival irrespective of biomarker status in patients with advanced epithelial ovarian cancer. This review focuses on the adverse events associated with niraparib and their management to maintain efficacy of niraparib treatment and improve quality of life for patients. In five trials assessing efficacy of niraparib in patients with advanced epithelial ovarian cancer (PRIMA, NOVA, NORA, QUADRA, and PRIME), treatment-emergent adverse events of any grade were reported in nearly all patients (≥99%) receiving niraparib; the events were grade ≥3 in 51–74% of patients. Across all lines of therapy, treatment-emergent adverse events led to dose interruptions in 62–80% of patients receiving niraparib and dose reductions in 47–71%. Hematologic events were most frequently reported, including thrombocytopenia, anemia, and neutropenia. Common non-hematologic events included gastrointestinal events, which were generally low grade (<5% were grade ≥3). Clinical strategies to manage these and other events, such as fatigue and insomnia, cognitive behavioral therapy and pharmacologic agents, are summarized. Once-daily niraparib dosing may be advantageous for some patients for many reasons, including night-time dosing which may help alleviate gastrointestinal symptoms. An individualized starting dose (determined by baseline body weight and platelet count) of niraparib demonstrated an improved safety profile while maintaining efficacy. Patients receiving the niraparib individualized starting dose had fewer grade ≥3 adverse events, dose interruptions, and dose reductions than patients receiving a fixed starting dose. The safety profile of niraparib across five pivotal studies in advanced epithelial ovarian cancer was consistent across multiple lines of treatment, including as maintenance therapy in first-line and recurrent settings and as treatment in heavily pre-treated patients. Long-term safety data from the NOVA ...
-
9دورية أكاديمية
المؤلفون: Herzog, Thomas J, Wahab, Shaun A, Mirza, Mansoor R, Pothuri, Bhavana, Vergote, Ignace, Graybill, Whitney S, Malinowska, Izabela A, York, Whitney, Hurteau, Jean A, Gupta, Divya, González-Martin, Antonio, Monk, Bradley J
المساهمون: GlaxoSmithKline
المصدر: International Journal of Gynecologic Cancer ; volume 33, issue 11, page 1733-1742 ; ISSN 1048-891X 1525-1438
الوصف: Objective Progression-free survival is an established clinically meaningful endpoint in ovarian cancer trials, but it may be susceptible to bias; therefore, blinded independent centralized radiological review is often included in trial designs. We compared blinded independent centralized review and investigator-assessed progressive disease performance in the PRIMA/ENGOT-ov26/GOG-3012 trial examining niraparib monotherapy. Methods PRIMA/ENGOT-ov26/GOG-3012 was a randomized, double-blind phase 3 trial; patients with newly diagnosed stage III/IV ovarian cancer received niraparib or placebo. The primary endpoint was progression-free survival (per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1), determined by two independent radiologists, an arbiter if required, and by blinded central clinician review. Discordance rates between blinded independent centralized review and investigator assessment of progressive disease and non-progressive disease were routinely assessed. To optimize disease assessment, a training intervention was developed for blinded independent centralized radiological reviewers, and RECIST refresher training was provided for investigators. Discordance rates were determined post-intervention. Results There was a 39% discordance rate between blinded independent centralized review and investigator-assessed progressive disease/non-progressive disease in an initial patient subset (n=80); peritoneal carcinomatosis was the most common source of discordance. All reviewers underwent training, and as a result, changes were implemented, including removal of two original reviewers and identification of 10 best practices for reading imaging data. Post-hoc analysis indicated final discordance rates between blinded independent centralized review and investigator improved to 12% in the overall population. Median progression-free survival and hazard ratios were similar between blinded independent centralized review and investigators in the overall population and across subgroups. Conclusion ...
-
10
المؤلفون: Matulonis, Ursula A., Walder, Lydia, Nøttrup, Trine J, Bessette, Paul, Mahner, Sven, Gil-Martin, Marta, Kalbacher, Elsa, Ledermann, Jonathan A, Wenham, Robert M, Woie, Kathrine, Lau, Susie, Marmé, Frederik, Casado Herraez, Antonio, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lindahl, Gabriel, 1971, Benigno, Benedict, Buscema, Joseph, Travers, Karin, Guy, Holly, Mirza, Mansoor R.
المصدر: Journal of Clinical Oncology. 37(34):3183-3191
الوصف: This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer.
وصف الملف: electronic
الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-164843Test
https://liu.diva-portal.org/smash/get/diva2:1417500/FULLTEXT01.pdfTest
النص الكامل